Yuan Yuanhong,Zhang Hui,Xiao Zhenghui,et al.Therapeutic effect of plasma exchange on antibody mediated rejection after living relative donor liver transplantation in children[J].Journal of Clinical Pediatric Surgery,2022,21(05):425-430.[doi:10.3760/cma.j.cn101785-202202012-006]
血浆置换治疗儿童亲属活体肝移植术后抗体介导排斥反应的疗效分析
- Title:
- Therapeutic effect of plasma exchange on antibody mediated rejection after living relative donor liver transplantation in children
- Keywords:
- Liver Transplantation/MT; Living Donors/CL; Plasma Exchange; Graft Rejection; Immuno- suppression; Treatment Outcome; Child
- 摘要:
- 目的 探讨血浆置换(plasma exchange,PE)治疗儿童亲属活体肝移植术后出现抗体介导排斥反应(antibody mediated rejection,AMR)的疗效。方法 以湖南省儿童医院1例因胆道闭锁、胆汁性肝硬化接受血型相合亲属活体肝移植,术后发生AMR的7月龄患儿为研究对象。该患儿肝移植术后一直使用他克莫司+泼尼松二联抗排斥治疗,术后1个月内出现以胆红素升高为主的肝功能异常,行移植肝穿刺活检,完善人类白细胞抗原(human lymphocyte antigen,HLA)抗体检测,并予血浆置换治疗。结果 肝穿刺活检结果提示急性排斥反应、补体C4d染色阳性,结合人类白细胞抗原(hu-man lymphocyte antigen,HLA)Ⅱ类特异性抗体阳性这一结果,确诊为供体特异性抗体(donor specific an-tibody,DSA)导致的AMR。确诊后予甲泼尼龙静脉冲击+静脉丙种球蛋白+吗替麦考酚脂口服治疗,并调整相关免疫抑制药物剂量,效果不理想,后加用血浆置换治疗,每2日1次,共5次,治疗1个月后患儿肝功能逐步恢复正常。截至目前已随访3年,复查过程中行移植肝穿刺活检5次,显示排斥反应逐步减轻,肝功能基本维持正常,未出现AMR复发。结论 血型相容的儿童亲属活体肝移植也可发生术后AMR,确诊后尽早联合血浆置换辅助治疗可能更有利于肝移植术后急性AMR的恢复。
- Abstract:
- Objective To explore the clinical efficacy of plasma exchange (PE) for antibody mediated rejection (AMR) after living relative donor liver transplantation. Methods Clinical data were retrospectively reviewed for a 7-month-old child with biliary atresia and biliary cirrhosis after living relative donor liver trans- plantation. Tacrolimus plus prednisone was prescribed for anti-rejection therapy after compatible blood type living relative donor liver transplantation. Liver function abnormality was caused predominantly by a postopera- tive elevation of bilirubin within 1 month. Then transplanted liver was biopsied and antibody test of human leu- kocyte antigen (HLA) performed. Results Liver biopsy revealed acute rejection reaction. Based upon the positive result of HLA II antibody and C4d, it could be confirmed as donor specific antibody (DSA) -induced AMR. The regimen was composed of intravenous methylprednisolone pulse, immunoglobulin, mycophenolate and immunosuppressive agents. However, the effect was not satisfactory. And then PE was performed every 2 days for a total of 5 sessions. After 1 -month treatment, liver function gradually normalized. Follow-up was conducted for 3 years. Transplanted liver was biopsied for 5 times and rejection gradually lessened and liver function basically stablized. There was no recrudescence of AMR. Conclusion Postoperative AMR occurs in children with com- patible blood type living relative donor liver transplantation. Early treatment plus PE may be more beneficial to the recovery of acute AMR after liver transplantation.
参考文献/References:
[1] Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants:manifestations, mechanisms, and thera- pies[J]. J Clin Invest, 2017, 127(7):2492-2504. DOI:10. 1172/JCI90597.
[2] Demetris AJ, Zeevi A, O’Leary JG. ABO-compatible liver allograft antibody-mediated rejection:an update[J]. Curr Opin Organ Transplant,2015,20(3):314-324. DOI:10. 1097/MOT. 0000000000000194.
[3] Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehen- sive Update of the Banff Working Group on Liver Allograft Pa- thology:Introduction of Antibody-Mediated Rejection[J]. Am J Transplant,2016, 16(10):2816-2835. DOI:10. 1111/ajt. 13909.
[4] Kim PT, Demetris AJ, O’Leary JG, et al. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the ’ two-hit hypothesis’[J]. Curr Opin Organ Transplant,2016,21(2):209-218. DOI:10. 1097/MOT. 0000000000000275.
[5] Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after ped- iatric liver transplantation[J]. Transplantation, 2015, 99(7):1416-1422. DOI:10. 1097/TP. 0000000000000796.
[6] O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated re- jection as a contributor to previously unexplained early liver al- lograft loss[J]. Liver Transpl,2014,20(2):218-227. DOI:10. 1002/lt. 23788.
[7] Grabhorn E, Binder TM, Obrecht D, et al. Long-term clinical rel- evance of de novo donor-specific antibodies after pediatric liver transplantation[J]. Transplantation, 2015, 99(9):1876-1881. DOI:10. 1097/TP. 0000000000000638.
[8] Tokodai K, Miyagi S, Nakanishi C, et al. Effect of recipient age at liver transplantation on prevalence of post-transplant donor-spe- cific hla antibody[J]. Ann Transplant,2017,22:333-337. DOI:10. 12659/aot. 903926.
[9] 宁禹, 张明满, 郭春宝, 等. 肝移植术后完全停用免疫抑制剂三例儿童临床特点分析[J]. 中华小儿外科杂志, 2017, 38(8):572-574. DOI:10. 3760/cma. j. issn. 0253-3006. 2017. 08. 004. Ning Y, Zhang MM, Guo CB, et al. Clinical characteristics of complete immunosuppression withdrawal in pediatric recipients:a report of 3 cases[J]. Chin J Pediatr Surg, 2017, 38(8):572-574. DOI:10. 3760/cma. j. issn. 0253-3006. 2017. 08. 004.
[10] Tokodai K, Miyagi S, Nakanishi C, et al. Impact of the trough lev- el of calcineurin inhibitor on the prevalence of donor-specific hu- man leukocyte antigen antibodies during long-term follow-up after pediatric liver transplantation:antibody strength and complement- binding ability[J]. Transplant Direct, 2017, 3(8):e196. DOI:10. 1097/TXD. 0000000000000713.
[11] Arias M, Rush DN, Wiebe C, et al. Antibody-mediated rejection:analyzing the risk, proposing solutions[J]. Transplantation,2014, 98(Suppl 3):S3-S21. DOI:10. 1097/TP. 0000000000000218.
[12] Cuadrado A, San Segundo D, López-Hoyos M, et al. Clinical sig- nificance of donor-specific human leukocyte antigen antibodies in liver transplantation[J]. World J Gastroenterol, 2015, 21(39):11016-11026. DOI:10. 3748/wjg. v21. i39. 11016.
[13] 王祥慧. 2019ATC器官移植国际前沿热点及新进展概述[J]. 器官移植,2020,11(2):222-233. DOI:10. 3969/j. issn. 1674-7445. 2020. 02. 007. Wang XH. Overview of international forefront hotspots and new progress on organ transplantation in 2019 ATC[J]. Organ Trans- plantation,2020,11(2):222-233. DOI:10. 3969/j. issn. 1674-7445. 2020. 02. 007.
[14] Valenzuela NM, Hickey MJ, Reed EF. Antibody subclass reper- toire and graft outcome following solid organ transplantation[J]. Front Immunol, 2016, 7:433. DOI:10. 3389/fimmu. 2016. 00433.
[15] Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific hla an- tibodies are associated with late allograft dysfunction after pediat- ric liver transplantation[J]. Transplantation,2015,99(7):1416-1422. DOI:10. 1097/TP. 0000000000000796.
[16] Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength:comparison of mfi, c1 q, and titer information[J]. Am J Transplant,2015,15(9):2421-2430. DOI:10. 1111/ajt. 13295.
[17] Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejec- tion:what is the clinical relevance?[J]. Curr Opin Organ Transplant,2017, 22(2):97-104. DOI:10. 1097/MOT. 0000000000000391.
[18] 巩颖, 郭晖, 钟自彪, 等. 肝移植后急性抗体介导的排斥反应一例诊断和治疗[J]. 中华器官移植杂志,2018,39(8):479-481. DOI:10. 3760/cma. j. issn. 0254-1785. 2018. 08. 007. Gong Y, Guo H, Zhong ZB, et al. Diagnosis and treatment of anti- body-mediated rejection after liver transplantation[J]. Chinese Journal of Organ Transplantation, 2018, 39(8):479-481. DOI:10. 3760/cma. j. issn. 0254-1785. 2018. 08. 007.
[19] 王凯, 王政禄, 孙超, 等. 儿童ABO血型不合肝移植术后抗体介导的排斥反应的诊治经验分析[J]. 实用器官移植电子杂志,2019,7(1):58-61. DOI:10. 3969/j. issn. 2095-5332. 2019. 01. 015. Wang K, Wang ZL, Sun C, et al. Experience in the diagnosis and treatment of antibody-mediated rejection after ABO blood group incompatibility liver transplantation in children[J]. Practical Journal of Organ Transplantation (Electronic Version), 2019, 7(1):58-61. DOI:10. 3969/j. issn. 2095-5332. 2019. 01. 015.
相似文献/References:
[1]周峻 王政 李龙 侯文英 谢华伟 崔龙 王文晓. 临时性门腔静脉架桥联合流出道改良重建在部分供肝肝移植中应用的实验研究[J].临床小儿外科杂志,2011,10(03):179.
[J].Journal of Clinical Pediatric Surgery,2011,10(05):179.
[2]单禹华,顾松,徐敏,等.小儿肝移植术后肠梗阻病因鉴别及预后分析[J].临床小儿外科杂志,2021,20(06):576.[doi:10.12260/lcxewkzz.2021.06.013]
Shan Yuhua,Gu Song,Xu Min,et al.Differentiation and prognosis of intestinal obstruction after pediatric liver transplantation[J].Journal of Clinical Pediatric Surgery,2021,20(05):576.[doi:10.12260/lcxewkzz.2021.06.013]
[3]夏强,朱欣烨.儿童肝移植发展现状及展望[J].临床小儿外科杂志,2022,21(05):401.[doi:10.3760/cma.j.cn101785-202202028-001]
Xia Qiang,Zhu Xinye.Current development and future outlook of pediatric liver transplantation[J].Journal of Clinical Pediatric Surgery,2022,21(05):401.[doi:10.3760/cma.j.cn101785-202202028-001]
[4]许陈诚,姜大朋.儿童肾脏移植中需要关注的供体因素[J].临床小儿外科杂志,2022,21(05):410.[doi:10.3760/cma.j.cn101785-202111027-003]
Xu Chencheng,Jiang Dapeng.Donor factors for kidney transplantation in children[J].Journal of Clinical Pediatric Surgery,2022,21(05):410.[doi:10.3760/cma.j.cn101785-202111027-003]
[5]高伟.扩大儿童肝脏移植供体来源途径[J].临床小儿外科杂志,2022,21(05):405.[doi:10.3760/cma.j.cn101785-202203014-002]
Gao Wei.Expanding the sources of donor pool for pediatric liver transplantation[J].Journal of Clinical Pediatric Surgery,2022,21(05):405.[doi:10.3760/cma.j.cn101785-202203014-002]
[6]刘辉,古力米热木·买买提江,李万富,等.儿童亲体肝移植11例回顾性分析[J].临床小儿外科杂志,2023,22(12):1124.[doi:10.3760/cma.j.cn101785-202306008-006]
Liu Hui,Gulimiremu Maimaitijiang,Li Wanfu,et al.Experiences of pro-liver transplantation in children:a report of 11 cases[J].Journal of Clinical Pediatric Surgery,2023,22(05):1124.[doi:10.3760/cma.j.cn101785-202306008-006]
备注/Memo
收稿日期:2022-2-7。
基金项目:国家十二五科技支撑项目（2012BAI04B01）；湖南省科技创新重点工程项目（2020SK10141-3）；湖南省科技厅重点实验室项目（2018TP1028）；湖南省卫生健康委课题项目（C2019019）
通讯作者:肖政辉,Email:xzh2010@163.com